Healthcare services company Agilon Health (NYSE: AGL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 7.2% year on year to $1.49 billion. On top of that, next quarter’s revenue guidance ($1.46 billion at the midpoint) was surprisingly good and 3.7% above what analysts were expecting. Its GAAP profit of $1.04 per share was significantly above analysts’ consensus estimates.

Is now the time to buy agilon health? Find out by accessing our full research report, it’s free.

Company Overview

Transforming how doctors care for seniors by shifting financial incentives from volume to outcomes, agilon health (NYSE: AGL) provides a platform that helps primary care physicians transition to value-based care models for Medicare patients through long-term partnerships and global capitation arrangements.

Revenue Growth

A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, agilon health grew its sales at an incredible 30.8% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. agilon health’s recent performance shows its demand has slowed significantly as its annualized revenue growth of 5.9% over the last two years was well below its five-year trend.

agilon health also reports its number of customers, which reached 549,000 in the latest quarter. Over the last two years, agilon health’s customer base averaged 3.1% year-on-year declines. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company’s products and services.

This quarter, agilon health reported year-on-year revenue growth of 7.2%, and its $1.49 billion of revenue exceeded Wall Street’s estimates by 2.8%. Company management is currently guiding for a 1.7% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.

agilon health’s adjusted operating margin has risen over the last 12 months, but it still averaged negative 3.7% over the last five years. This is due to its large expense base and inefficient cost structure.

Analyzing the trend in its profitability, agilon health’s adjusted operating margin might have fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

In Q2, agilon health generated an adjusted operating margin profit margin of 2.4%, up 9.5 percentage points year on year. This increase was a welcome development and shows it was more efficient.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

agilon health’s full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it’s at a critical moment in its life.

In Q2, agilon health reported EPS of $1.04, up from negative $0.25 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects agilon health to perform poorly. Analysts forecast its full-year EPS will invert from $3.25 to negative $3.21.

Key Takeaways from agilon health’s Q2 Results

We were impressed by agilon health’s optimistic EBITDA guidance for next quarter, which blew past analysts’ expectations. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this quarter featured some important positives. The stock traded up 2.6% to $110.51 immediately following the results.

agilon health had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).